Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study

Table 2

Baseline characteristics of participants with and without cardiovascular drug treatment.

Variable	No cardiovascular drug treatment ()	Cardiovascular drug treatment ()	value
Age, mean (SD), years	55.58 (10.9)	57.95 (10.63)	0.092
Sex, men	226 (42.2%)	34 (51.5%)	0.188
Smoking status			0.495
Yes	105 (19.6%)	17 (25.8%)
Former	260 (48.5%)	29 (43.9%)
Cholesterol, mean (SD), mmol/L	6.38 (1.25)	6.37 (1.12)	0.927
HDL-C, mean (SD), mmol/L	1.39 (0.45)	1.37 (0.43)	0.858
LDL-C, mean (SD), mmol/L	4.41 (1.18)	4.39 (1.03)	0.888
Triglycerides, mean (SD), mmol/L	1.97 (1.5)	1.91 (1.03)	0.734
Diastolic blood pressure, mean (SD), mmHg	77.44 (9.62)	79.85 (11.05)	0.094
Systolic blood pressure, mean (SD), mmHg	134.66 (17.44)	136.48 (19.66)	0.473
Hypertension, yes	36.6%	42.4%	0.427
Self-reported diabetes, yes	39 (7.3%)	12 (18.2%)	0.006
Familial CVD			0.036
Yes	93 (17.4%)	5 (7.6%)
Do not know/missing value	393 (73.3%)	58 (87.9%)
Cardiovascular risk score	2.71 (3.42)	3.92 (4.63)	0.043
Statins			0.135
Atorvastatin	42 (7.6%)	2 (4.5%)
Rosuvastatin	31 (5.9%)	0 (0%)
Simvastatin	455 (84.9%)	61 (92.4%)
Other statin	9 (1.7%)	2 (3.0%)
Dose^a			0.341
Medium	399 (63.2%)	43 (65.2%)
High	31 (5.8%)	1 (1.5%)
Adherence			0.077
Low (0-80%)	223 (41.6%)	35 (53%)

Notes: ^aSee Table 1 for grouping of doses. Abbreviations: CVD: cardiovascular disease; CVE: cardiovascular event; H(L)DL-C: high- (low-) density lipoprotein cholesterol; SD: standard deviation.